<DOC>
	<DOCNO>NCT01760694</DOCNO>
	<brief_summary>To assess ability combination update approved modality treatment first line pancreatic cancer patient increase time Progression Free Survival</brief_summary>
	<brief_title>Multi-Modality Therapy Untreated Patients With Resectable Marginally Resectable Pancreatic Cancer</brief_title>
	<detailed_description>For resectable patient ; surgery Intraoperative Radiation Therapy ( IORT ) . Radiation Therapy within 6-8 week surgery follow FOLFIRINOX every 2 week start within 12 week surgery . For marginally resectable patient ; patient 2-3 cycle neoadjuvant chemotherapy FOLFIRINOX restaged , undergo surgery IORT within 2-4 week follow chemotherapy . Then radiation therapy start within 6-8 week . Followed FOLFIRINOX every 2 week start within 12 week surgery total 2-4 cycle .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologically proven Exocrine Adenocarcinoma pancreas Clinically resectable marginally resectable disease No prior radiation chemotherapy carcinoma pancreas ECOG performance status 01 Patients must medically able undergo surgical resection Patients child bear potential must follow study specific precaution Women lactate exclude condition dispose breast milk . Adequate hematologic biochemical parameter . Prior treatment pancreatic cancer . Concurrent investigational treatment . Unresectable pancreatic mass . Neuroendocrine Histological pancreatic cancer Distant Metastatic disease Any condition , option investigator , would compromise well patient anything would prevent patient meeting perform study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Intraoperative Radiation Therapy</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>